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Resumo 
Os boronatos e ácidos borónicos são historicamente conhecidos pela sua importante 
aplicação em reações de acoplamento de Suzuki. Para além da sua importância em 
síntese orgânica, os ácidos borónicos também são encontrados em aplicações no 
campo do design de fármacos, substituindo grupos funcionais como ácidos 
carboxílicos de modo a alterar as propriedades físico-químicas de candidatos a 
composto líder. Contudo, poucos derivados de ácidos borónicos foram sintetizados 
para estudos biológicos devido a dificuldades associadas à sua preparação. 
Recentemente, também se descobriu que o calcitriol (a forma ativa da vitamina D3) 
ativa pelo menos 229 genes associados a diversas doenças, incluindo artrite, diabetes 
e cancro, sugerindo que o calcitriol pode possuir uma gama mais alargada de funções 
biológicas do que inicialmente pensado. Estudos sobre a relação estrutura-função de 
numerosos análogos do calcitriol demonstraram que os seus efeitos calcémicos 
podem ser significativamente reduzidos durante atividades de diferenciação celular, 
não tendo sido desvendado o mecanismo exato. Neste projeto levou-se a cabo a 
síntese de um análogo de Vitamina D contendo um éster borónico na cadeia lateral, de 
modo a melhorar a sua interação com o recetor da vitamina D (VDR) e tendo em vista 
futuros ensaios pré-clínicos. 
Palavras-chave: Vitamina D, Ácidos borónicos, Ésteres borónicos, Acoplamento de 
Suzuki, Cross metathesis, Síntese, Calcitriol, VDR, LBD, Docking 
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Abstract 
Boronates and boronic acids have an important application in Suzuki coupling 
reactions. Apart from their role (significance) in organic synthesis, boronic acids find 
applications in the drug discovery field, replacing structural motifs such as carboxylic 
acids or hydroxyl moieties to alter the physicochemical properties of lead candidates. 
However, relatively few alkyl boronic acid derivatives have been synthesized or 
biologically evaluated, due to problems associated with their preparation. Recently, it 
was also found that 1α,25-dihydroxyvitamin D3 (1,25D or calcitriol, the active form of 
vitamin D3) activates at least 229 genes associated with several diseases, including 
arthritis, diabetes and cancer, suggesting that 1,25D might be involved in a broader 
range of biological functions than originally thought. In an attempt to combine the 
biological properties of 1,25D with the advantages of boron chemistry, several vitamin 
D analogs containing borononic groups have been designed and docked in the ligand 
binding domain of the vitamin D receptor. Hence, it was carried out the synthesis of a 
theoretically highly active boronic ligand of the vitamin D receptor (VDR), with a view 
on preclinical studies. 
Key words: Vitamin D, Synthesis, Boronic acid, Boronic ester, Suzuki coupling, Cross 
metathesis, , Calcitriol, Vitamin D receptor, Ligand binding domain, Vitamin D analogs, 
Docking. 
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Introduction 
1. Vitamin D Discovery 
In 1919, Sir Edward Mellanby was the first to confirm that rickets was a dietary 
deficiency disease. To do so, he fed dogs a typical Scottish diet (Scottish people had 
the highest incidence of rickets), and the dogs developed rickets identical to the human 
disease. He therefore postulated that the disease was developed after “a diminished 
intake of an anti-rachitic factor, which is either [McCollum’s] fat-soluble factor A, or has 
a similar distribution to it”.[1] 
McCollum, in 1922, decided to test whether vitamin A was responsible for the healing 
of rickets,[2] and this test is acclaimed to be the key experiment in the discovery of 
vitamin D.[3] The observation that oxidized cod-liver oil could not prevent xerophthalmia 
but could prevent rickets in rats, showed that “oxidation destroys fat-soluble factor A 
without destroying another substance which plays an important role in bone growth”.[3] 
The resulting conclusion was that fat-soluble factor A was composed of two 
substances, one termed later “vitamin A” and the newly discovered antirachitic factor, 
which was named vitamin D2.
[4] 
Years later, it was discovered[3] that the natural form of vitamin D in the human 
organism was vitamin D3 (Figure 1). 
 
Figure 1. Structure of Vitamin D3 and its active metabolite 1,25D (calcitriol). 
Vitamin D3, through is active form 1,25D (1α,25(OH)2D3 ; calcitriol), is responsible for 
the calcium and phosphorous homeostasis. Besides these classical functions, this 
hormone also plays a role in the control of cellular proliferation and differentiation, 
cellular apoptosis and immune system. These characteristics led to the application of 
1,25D in the treatment of diseases such as osteoporosis, psoriasis and different types 
of cancer.[5, 6] 
20 
FCUP | ICBAS | USC 
Introduction  
 
2. Structure and Nomenclature 
The natural form of vitamin D in biological systems was discovered by Windaus and 
named vitamin D3. It is produced  in the skin by UV irradiation of 7-dehydrocholesterol 
(7-DHC)[7] and biologically transformed to an active hormone, calcitriol, through 
enzymatic transformations.  
 
Figure 2. Structure and nomenclature of 7-dehydrocholesterol, vitamin D3 and calcitriol. 
Vitamin D is classified as a steroid hormone, being included in the same category of 
other classical hormones, such as testosterone, estradiol, cortisol or aldosterone. 
Steroids are natural compounds that present a common basic structure of four fused 
rings (A to D).[8]  
Vitamin D and its derivatives are part of a subtype of steroids called secosteroids, and 
they display a triene system as a result of a photochemical rupture of C9-C10 bond 
from ring B of the steroid precursor (7-DHC). 
In comparison to other steroidal hormones, vitamin D3 and its metabolites have high 
conformational flexibility, mainly due to the presence of a triene system and a side 
chain (Figure 3). 
 
Figure 3. Structure and nomenclature of vitamin D3 and its steroidal precursor. 
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3. Vitamin D Metabolism 
Vitamins are defined as heterogeneous compounds without energetic value that can 
only be obtained through diet and cannot be synthesised by the organism. Though 
vitamin D3 is classified as a vitamin due to historical factors, it can be obtained through 
diet or via UV light mediated endogenous transformation in the epidermis.  
In terms of diet, vitamin D3 is obtained in significant quantities through the ingestion of 
fish oils, mushrooms, egg yolk or even liver. Nowadays, some milks, cereals or juices 
are enriched with vitamin D3, to ensure the ingestion of the dietary reference intake of 
vitamin D.[9] 
Despite the referred dietary sources of vitamin D3, its endogenous transformation in the 
skin is still the most important and accountable source of this vitamin.[10] 
Vitamin D is produced in the skin as a result of solar exposure in a process that 
involves the photolysis of epidermal 7-DHC (provitamin D) and consequent conversion 
in previtamin D3 (Scheme 1). This previtamin, through a process of antarafacial 
sigmatropic shifting of hydrogens is converted into vitamin D.[11] Lumisterol and 
taquisterol are also produced from previtamin as by-products. 
 
 
Scheme 1. Metabolic route of vitamin D formation in the skin. 
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However, this metabolite is not active in this form and must be activated downstream to 
portray its biological functions. Therefore, the vitamin undergoes a hydroxylation in the 
liver, catalysed by CYP2R1, a 25-hydroxylase, member of the cytochrome P450 
superfamily of enzymes to afford 25(OH)D3.
[12] This enzyme is reported to be one of 
the most important 25-OHases, since its deletion in genetic studies leads to a vitamin D 
dysfunction phenotype.[13] The metabolite 25(OH)D3 is transported in the blood mainly 
by association with the vitamin D binding protein (DBP). 
The second hydroxylation occurs in the distal tubules of the kidney, under the action of 
the mitochondrial CYP27B1, giving place to the final and active hormone, 
1α,25(OH)2D3 (1,25D; calcitriol).
[14] 
 
Scheme 2. Biological activation of vitamin D3 
This hormone has widespread biological effects and, as such, its action is rigorously 
controlled by different enzymes. The degradation pathway is accomplished via the 
CYP27A1, a microsomal enzyme that is constitutionally expressed in the kidney and 
stimulated by 1α,25(OH)2D3.
[15] This pathway leads to the oxidative rupture of the side 
chain, via hydroxylation of 1α,25(OH)2D3 at carbon 23 or 24 to give  
1,24,25-trihydroxyvitamin D3 [1,24,25(OH)3D3] or 1,25-hydroxyvitamin  
D3-26,23-lactone, respectively.
[16] Each oxidation leads to distinct metabolites that lack 
the biological activity of the hormone. One of the final products of this route is calcitroic 
acid, which is biologically inert and hydrosoluble, easing its excretion in the urine. 
Deletion studies on the gene CYP27A1 show a hypercalcemic and hypercalciuric 
phenotype,[17] that were later attributed to the toxicity induced by high amounts of 
circulating 1α,25(OH)2D3. 
Calcitriol is also tightly controlled by endocrine factors parathyroid hormone (PTH) and 
the fibroblast growth factor 23 (FGF23). 
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The important endocrine feedback circuit involves the 1α,25(OH)2D3 high levels acting 
to suppress the CYP27B1 gene, to downregulate PTH secretion and to increase the 
expression of FGF23 in bone tissues. 
Understanding the molecular foundations for the regulation of CYP27B1 and CYP27A1 
by their primary regulators, PTH, 1α,25(OH)2D3 and FGF23 is of utmost importance, 
since it allows the better comprehension of diseases that implicate the production and 
degradation of vitamin D.  
4. Mode of Action of 1α,25(OH)2D3 
The steroid hormone 1α,25(OH)2D3, as other steroid hormones, exerts its biological 
functions through the regulation of gene transcription, called the classical genomic 
responses, or through the activation of a series of rapid transduction signal pathways at 
the plasma membrane, called the rapid or nongenomic responses. 
4.1. Genomic actions and Vitamin D Receptor 
The genomic actions of vitamin D are a result of the interaction of the active hormone, 
1,25D, with the nuclear vitamin D receptor (VDR) in a very stereospecific way, binding 
1α,25(OH)2D3 with high affinity (Kd ≈ 0.5 nmol/L).
[18] 1,25D enters the cells through 
passive diffusion, after being transported from the kidneys associated with the vitamin 
D binding protein (DBP). Binding of the 1,25D with VDR leads to a conformational shift 
of VDR at the C-terminal and induces heterodimerization between VDR and the 
retinoid X receptor (RXR). This alteration also enables the region termed AF-2 on the 
VDR to interact with other proteins like transcription factors, including coactivator 
proteins such as SRC-1.[19] The 1,25D-VDR-RXR-CoA complex then binds to certain 
DNA sequences named response elements (VDREs) at the promoter sites of the 
targeted genes, leading to gene transcription (Figure 4).[20] 
24 
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Figure 4. Mode of action of 1α,25(OH)2D3 
 
A vast amount of work on VDR coactivators has unveiled that these proteins may 
possess intrinsic histone acetylase activity, being essential for gene transcription. 
4.1.1. The vitamin D receptor 
The VDR was first found in the chicken intestine[21], with the human and rat VDR being 
found shortly after. Its biochemical properties, including its ability to bind DNA were 
only unveiled later and showed similarities to other steroid hormones receptors. 
The VDR is phylogenetically conserved, with the human VDR having only 4 more 
amino acids at the N-terminal chain when compared to the rat analogous. it has  two 
different domains: the DNA-binding domain (DBD) and the ligand-binding domain 
(LBD, Figure 5). At the N-terminus is a truncated A/B domain of 22 aminoacids with few 
described activities. The DNA-binding domain, also called the C region, contains two 
zinc fingers. A small D region, or hinge domain, provides flexibility to the protein and 
links the DBD to the LBD. The LBD is a complex region accountable for the high-affinity 
binding of the ligand, for the dimerization with RXR and for the binding to transcription 
factors. 
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Although the crystalline structure of the entire VDR has not yet been unravelled, the 
structures of the separate domains are known and enable us to study different 
interactions within the protein. 
 
Figure 5. Schematic view of amino acid sequences of the human Vitamin D Receptor (VDR). 
4.1.1.1 DNA binding domain  
As previously mentioned, the VDR possesses a conserved DNA binding domain (DBD) 
that consists of two zinc atoms coordinated by 8 histidine residues in a geometry that 
resembles a tetrahedron.[22] The zinc finger closer to the N-terminus is responsible for 
the binding to the DNA VDREs, while the other zinc finger helps stabilize the 
dimerization with RXR 
The DBD contains two α helixes (H1 and H2) that are packed together in a 
perpendicular angle, with the hydrophobic residues facing the DNA. Helix H1 is 
responsible for the binding to DNA, as it binds to repeats of 5’-AGAACA-3’ palindromic 
sites and thus inserts itself in the DNA major groove.[23] 
Water molecules also play a role in the interaction between the VDR and the DNA by 
bridging the gap between protein side chains and DNA functional groups.[24] 
4.1.1.2 Ligand Binding Domain  
This highly variable C-terminus domain is responsible for the high affinity between the 
protein and the 1α,25(OH)2D3 hormone. 
In the human VDR, the LBD has an insertion domain between residues 143 and 223 
(connecting helices H1 and H3). This insertion domain is highly variable between 
species and does not have any recognized biological function. Structurally, this 
insertion domain has few short β strands and high percentage of negatively charged 
residues, which may explain the weak VDR stability and high nonspecific contacts that 
interfere with crystallization procedures.[25] Indeed, Moras and colleagues, 
hypothesized that the presence of this segment in the VDR was the reason the first 
26 
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attempts to obtain the crystal structure of the LBD failed. They successfully managed to 
create a mutated VDR that lacked the flexible insertion domain. Since the mutated 
region is far from the aminoacids that interact with the ligand or with corepressors and 
coactivators, it should not interfere with the biological functions of the receptor.[26] The 
structure of the mutated VDR complexed with 1,25D and other synthetic agonists was 
obtained (Figure 6).[25] 
The global construction of the VDR LBD is similar to other nuclear receptors LBDs, 
presenting 13 α helices in a 3-layer sandwich structure, as well as 3 stranded β sheet. 
It is suitable to note that the structure of the helix H1 and its relative position in the LBD 
allows the stabilization of its global structure by intramolecular contacts. Localized in  
C-terminus, the H12 helix is a crucial component of the LBD, as its interactions with 
different ligands provide a critical control of the agonists/antagonists actions on the 
nuclear receptor. Furthermore, H12 contains a seven aminoacids region, the ligand 
dependent activation function (AF-2) that acts as a molecular switcher in response to 
the ligands.[27] 
 
Figure 6. Crystallographic structure of LBD bound to calcitriol (PDB: 1DB1). 
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4.1.1.3 VDR ligand stabilization network 
Understanding the key molecular interactions between calcitriol and its receptor is 
essential to interpret how changes in the ligand can modulate the biological responses. 
Detailed analysis on the crystal structure of the VDR’s LBD complexed with its natural 
ligand has provided comprehensive insights on the most important  
ligand-receptor interactions.[28] 
The 1α,25(OH)2D3 adopts a β-chair conformation in the VDR pocket, with the C1α-OH 
and C3β-OH in equatorial and axial orientation, respectively. 
The conjugated triene system connecting the A ring to the CD bicycle, shows an 
almost trans conformation with a torsion angle on the C6-C7 bond of -149º, inside the 
receptor. This torsion makes the ligand adopt an overall curved geometry, unlike the 
ligand in an unbound state, which presents a planar geometry. A hydrophobic channel 
surrounds the triene system, stabilizing its conformation, through van der Waals 
interactions with aminoacids Ser-275 (H5), Trp-286 and Leu-233 (H3). 
The C ring also interacts with Trp-286 (on the α face), whereas the methyl on C18 
reaches out to the Val-234 on the H3 helix. 
 
Figure 7. General view of calcitriol in the binding pocket. 
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Regarding the A ring, the C1α-OH group forms hydrogen bonds with Ser-237 (H3) and 
Arg-274 (H5), while the C3-OH group makes hydrogen bonds with residues Ser-278 
(H5) and Tyr-143 (loop H1-H2). 
The side chain at C17 adopts an extended conformation parallel to the C13-C18 bond 
and is surrounded by hydrophobic residues. These interactions are thought to keep the 
active conformation of the ligand while bound to the LBD.[29] 
At the end of the side chain, C25-OH interacts with His305 and His397, through 
hydrogen bonds. In addition, the H12 helix in its active configuration also establishes 
van der Waals interactions with the methyl C27, through Val-418 and Phe-422. 
It is also important to point out the fact that the ligand binding cavity of the hVDR is 
large, with the ligand only occupying 56% of the total available volume. Additional 
space is observed near the A ring, as well as in the side chain, which could allocate 
several types of modified new ligands. 
 
Figure 8. Key molecular interactions of calcitriol in the binding pocket. 
4.2. Non-genomic actions 
Vitamin D was initially thought to only act on genomic level, as discussed above, and it 
was not until later that some actions were considered too rapid to be accounted as 
changes at a genomic level. 
It is presently recognized that 1α,25(OH)2D3 has non-genomic actions that essentially 
manifest as the activation of signaling molecules (PLC, PLA2, PI3K, p21ras) and 
rapidly generated second messengers, such as Ca2+, cAMP or fatty acids. These 
effects can be accompanied by the activation of protein kinases, protein kinase A, MAP 
kinases, PKC or Ca2+-calmodulin kinase II, for example.  
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In terms of large scale effects, the non-genomic actions of 1,25D are responsible 
for:[30] 
 Opening of Ca2+ and Cl- channels; 
 Rapid increase in the absorption of calcium at the intestinal level; 
 Insulin secretion by β pancreatic cells; 
 Quick migration of endothelial cells; 
 Decreasing of PTH secretion; 
 Stimulation of osteoclastic bone resorption; 
 Decreasing production of collagen type I. 
Further research led to the characterization of a new receptor[31] besides VDR that 
may mediate rapid responses, named membrane-associated rapid response steroid 
(MARRS). This receptor is located on the cell membrane or in the perinuclear area, 
within lipid rafts, but not on the nucleus. 
In conclusion, the non-genomic actions of vitamin D are yet superficially studied in 
comparison to the genomic actions. Future research on this field will help to elucidate 
the mechanisms by which these actions are accomplished. 
5. Biological Activity of Vitamin D 
The hormone 1α,25(OH)2D3 is implied in a wide variety of biologic processes that can 
be classified as classical and non-classical functions. The classical functions are 
responsible for the calcium and phosphate homeostasis. The non-classical functions 
encompass cell differentiation and proliferation processes, modulation of immune 
responses and control of tissue malignancy progression.  
 Calcium Homeostasis 
Through its interaction with many proteins, calcium is involved in different aspects of 
the organism, such as neuronal transmission, enzymatic regulation, muscle contraction 
or cell differentiation. Such diverse functions are controlled through a tight regulation of 
cellular compartments and extracellular fluids, by the activity of several calcium 
ATPases, channels and exchangers located in plasmatic membranes and endoplasmic 
reticulum membrane. 
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This homeostasis involves the cooperation between the kidneys, the intestine, the liver, 
the parathyroid gland and the skeleton, in which the 1α,25(OH)2D3 hormone plays a 
major role (Figure 9). 
 
Figure 9. Overview of the calcium homeostasis. 
 PTH Regulation 
Parathyroid hormone, PTH is produced in the parathyroid gland. PTH in the blood will 
induce 1α-hydroxylase in the kidney, inducing 1α,25(OH)2D3 production.  
In a negative feedback loop, the newly synthesized calcitriol will act on the parathyroid 
gland in two ways. First, it interacts with VDR that is expressed in this gland, acting on 
a negative VDRE here located, exerting suppression of PTH production[32]. It also 
increases parathyroid sensitivity to Ca2+ inhibition by increasing the expression of 
calcium sensing receptor (CaSR), further regulating PTH levels.[33] This enables the 
regulation of PTH production and the proliferation of the gland 
These actions of 1α,25(OH)2D3 are manipulated in the clinical practice as a method of 
treating secondary hyperparathyroidism in renal failure.[34] 
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 Intestinal Calcium Absorption 
Vitamin D is reported to be essential in enhancing the absorption of intestinal ions, 
calcium and phosphate, mainly in the duodenum portion.[35] Experiments with mice 
lacking VDR, 1α-hydroxylase or both, have evidenced that these mice express the 
same phenotype visible in patients with vitamin D-dependent rickets.[36] This shows 
that 1α,25(OH)2D3 and VDR are both needed for an efficient intestinal calcium 
absorption. 
Calcium uptake in the intestinal cells is accomplished in a transcellular fashion, 
mediated by active transport trough the interior of the cells and also by paracellular 
transport, which does not require energy and can be found throughout the intestine. 
 Renal Calcium Reabsorption 
In the kidney, the most important endocrine effect of 1α,25(OH)2D3 is its own 
regulation, as there is an increase of the levels of 24-hydroxylase and a suppression of  
1α-hydroxylase. Calcitriol is also involved in the reabsorption of calcium in the nephron, 
mainly in the proximal tubules.[37] 
Similarly to intestinal absorption, renal reabsorption is accomplished via paracellular 
and transepithelial transport, the latter occurring in three steps. 
VDR and 1α,25(OH)2D3 play an important role in modulating calcium renal reabsorption 
through the upregulation of proteins such as D28k, NCX1 and TRPV5.[21] 
 Bone Calcium Regulation 
Vitamin D is also essential to the development and maintenance of the skeleton, by 
regulating the calcium uptake and release in osteoblasts and osteoclasts.  
Osteoblasts are responsible for the promotion of bone formation, while osteoclasts 
break bone tissue and release calcium. Osteoblasts express a surface ligand, RANKL, 
which can bind protein RANK, which is expressed in osteoclast cells, or 
osteoprotegerin (OPG), a soluble ligand osteoblast-derived. When RANKL binds RANK 
on the osteoclast surface, it triggers a signaling cascade that leads to differentiation 
and maturation of osteoclasts. OPG acts as a decoy for RANK, disrupting  
RANKL-RANK interactions and binding RANKL in a competitive way, inhibiting 
osteoclast development.[38] 
Calcitriol and PTH are modulators of bone resorption, as they enhance the expression 
of RANKL and inhibit OPG formation. Both 1α,25(OH)2D3 and VDR conjoined actions 
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are needed to ensure optimal osteoblastic bone formation and osteoclastic bone 
resorption.[39] 
 Suppression of cell growth 
There has been evidence that 1α,25(OH)2D3 inhibits clonal proliferation in several 
cancerigenous cell lines and promotes its differentiation towards less aggressive 
phenotypes. 
The mechanisms known to date suggest that 1,25D can arrest the malign cell cycle in 
the G0/G1 phases. It also induces the expression of cyclin-dependent kinase inhibitors 
p21 and p27, promotes the sequestering of activated EGRF into endosomes or even 
enhances the expression of C/EBPβ, leading to diminished cellular proliferation. 
 Apoptosis Regulation 
Calcitriol induced apoptosis enables the control of hiperproliferative disorders. 
In breast and prostate cancer cells, 1,25D induces apoptosis through the modulation of 
pro-apoptotic proteins, such as Bax and increases the intracellular Ca2+ concentration 
that leads to the activation of several caspases. Further studies in MCF7 cell lines 
elicited that calcitriol increases the effects of ionizing radiation in these cells. 
In contrast to the pro-apoptotic effect in malign cells, calcitriol exerts protective effects 
in normal cells, as it protects against UV-radiation or chemotherapy induced apoptosis.  
 Modulation of immune responses 
1α,25(OH)2D3 is effective in controlling infections, autoimmune diseases and tolerance 
to transplants, mainly by inducing differentiation of macrophages, antigen-presenting 
cells, dendritic cells and lymphocytes.  
Several infectious diseases are known to be related to vitamin D deficiency, such as 
tuberculosis. 1α,25(OH)2D3 is also known to potentiate the destruction of microbes. 
Furthermore, lack of vitamin D is associated with some autoimmune diseases, for 
instance, Crohn’s disease, multiple sclerosis or type 1 diabetes. 
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6. Vitamin D3 Analogs 
In order to induce the aforementioned physiological effects in the clinic, 
supraphysiological doses of 1,25D would have to be administered. This, however, 
would result in in vivo calcemic side effects, like hypercalcemia and hypercalciuria.  
In this sense, several calcitriol analogs were developed to minimize these negative 
calcemic side-effects, while preserving or even enhancing the beneficial effects of the 
hormone. Some of the synthesized compounds are tissue-specific, have low calcemic 
properties and can be administrated in higher doses when compared with the native 
hormone.[40] 
Nowadays there are more than 3000 published analogs that were synthesized by 
pharmaceutic industries and academic institutions. Most of the existing analogs are 
agonists of the VDR receptor, although some antagonists and inverse agonists can be 
found.[41, 42] 
All of the analogs interact with the VDR-LBD region and their adopted conformation 
inside the receptor characterizes their functional profile. The interactions between 
these analogs and the VDR are best analysed by crystal structures, which provide 
detailed information about the molecular strucutres of the analogs inside the 
receptor.[25] 
6.1. Clinically Approved Analogs 
On the present day, almost all positions of the vitamin D structure have been modified 
in order to create new analogs. Most of the modifications are produced in the side 
chain since it is directly related to the biologic response and selectivity of the 
compounds. The integrity of the triene system is essential for the biological activity of 
the vitamin and therefore few analogs have alterations at this site. The CD bicycle is 
also usually left untouched, due to lack of information on the structure-activity 
correlation and to the difficulty in synthesizing such compounds. 
The main goal of developing analogs is their therapeutic application in proliferative 
diseases (such as psoriasis), in bone disorders (such as osteoporosis) and in different 
types of cancer.[6] 
Paricalcitol and doxercalciferol are two clinically approved analogs used to treat 
secondary hyperparathyroidism. Falecalcitriol and maxacalcitol are also used with the 
same goal but are exclusively used in Japan. All these compounds have the ability to 
decrease the elevated levels of circulating PTH by supressing it.[43] 
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Tocalcitol, calcipotriol and, more recently, maxacalcitol are used to treat psoriasis. 
They can be administrated as monotherapy or used in combination with topic steroids. 
They have pro-differentiation and anti-proliferative effects on keratinocytes.  
In the case of osteoporosis, the existing analogs in clinical trials, alfacalcidol and 
eldecalcitol, are only tested in Japan. Their use increases bone mineral density and 
reduces the risk of new vertebral fractures.[44, 45] 
Figure 10 shows some calcitriol analogs that have clinical application. 
 
Figure 10. Overview of clinically approved vitamin D analogs. 
6.2. Boron in Drug Design 
It was only recently that the carbon neighbour, boron, began to catch the attention of 
researchers and pharmaceutical industries. Nowadays, boron is being investigated as 
an alternative to carbon in drug design.[46] 
There are interesting differences between carbon and boron. The latter possesses both 
metallic and non-metallic characteristics since it can form oxides and salts [B2O3, 
B2(SO4)3] as well as acids (H3BO3). 
Boron is a trivalent metal but, unlike a metal, it has great electron affinity that results 
from its vacant p-orbital. The charge distribution allows the formation of  
non-covalent bonds, needed to form transient connections with active sites that are 
important in several biochemical reactions. 
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Given this structural and electronic aspects, boron compounds can give rise to a new 
generation of drugs, capable of binding to target molecules not accessible to  
carbon-based compounds. 
In this endeavour, the first boron-based drug, Velcade® (bortezomib; Millennium 
Pharmaceuticals, Boston, MA, USA, Figure.11), was designed and clinically tested as a 
proteasome inhibitor for the treatment of multiple myeloma. The drug successfully 
passed phase III trials and received several regulatory approvals from FDA (US Food 
and Drug Administration) and by the EMEA (European Medicines Agency)[47]. Initially, 
Velcade® was used in confined cases but was later extended to treat newly diagnosed 
myeloma patients. 
 
Figure 11. Bortezomib, marketed as Velcade® by Millennium Pharmaceuticals. 
6.3. Boron in BNCT 
Aside from drug design, boron also plays an important role in Boron Neutron Capture 
Therapy (BNCT).[48, 49] This therapy takes advantage of the nuclear reaction that 
occurs when the stable boron isotope, boron-10 (10B) is irradiated with low-energy 
neutrons.  
Boron and the neutrons are, on their own, usually inoffensive to the cells. However, 
when boron atoms are irradiated with a stream of neutrons, the B-10 atoms fissure and 
produce (4He) α particles that have a high cytotoxic effect,. Furthermore, this reaction 
only exerts its effects in cells that accumulated boron and therefore it is harmless to the 
surrounding tissue. The main challenge is to develop boron compounds that can be 
taken up by cancer cells selectively.  
The instruments used to produce the low-energy neutron beams are also a challenge 
to overcome, since it requires special nuclear reactors that are not affordable or 
accessible to most hospital centres.[50] 
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6.4. Boronic Acids  
The utility of boronic acids is intimately connected to their unique electronic and 
physicochemical properties. In organic synthesis there are many boron-based 
reagents, which reflects its usefulness in the world of organic chemistry.[51] 
One of the properties of boronic acids is their strong Lewis acid character, due to the 
boron open shell. Most phenylboronic acids present a pKa in the 4.5-8.8 range. Upon 
different substitutions, boronic acids can readily convert from a trigonal planar neutral 
sp2 boron to a tetrahedral anionic sp3 boron, under physiological conditions. This 
conversion makes these compounds good transition state analogs for inhibitors of 
hydrolytic enzymes.[52] Indeed, nowadays, there are boronic analogs used as 
enzymatic inhibitors of several enzymes, such as peptidases, proteases, 
transpeptidases as well as nitric oxide synthase (NOS). 
 
Figure 12. Conversion of boronic acids under physiological conditions. Adapted from Yang, et al. 2003.[53] 
Another application of boronic acids is the already mentioned BNCT, where the unique 
properties of the boron-10 isotope are exploited. The intent is to establish a targeted 
delivery of boron-carrying compounds, in high concentration, to cancer cells. By doing 
so, these compounds would be ideal for localized radiation therapy. 
One more potential use for boronic acid compounds is the creation of  
feedback-controlled delivery systems for insulin. The idea comes from the fact that 
boronic acids can interact with dihydroxylated compounds, for instance, sugars. The 
ideal controlling signal for this application would be glucose concentration changes. 
The goal would be to create boronic acid polymers that could store insulin in their 
interior and upon a change in glucose concentration, detected by the interaction 
between glucose and boronic acids on the polymer surface, the polymer would change 
its permeability and release insulin into the blood stream.   
Given the biological applications of boronic acids, and the many potential compounds 
that can be designed, this field of investigation has yet to be fully exploited.
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Objectives 
Given the growing number of applications for boron ligands in the drug discovery field, 
this work focuses on the development of boronic acid and boronic ester analogs of 
1α,25(OH)2D3, with a view on biological studies. 
For this purpose, the main objectives of this thesis are: 
1. Docking of new boronic 1,25D analogs into the crystallographic structure of the 
VDR(LBD) complex to explore their in silico affinity for the VDR;  
2. Synthesis of the analogs that showed higher theoretical affinity towards the 
receptor. Figure 13 shows the chosen analogs to be synthesized (A4 and E4). 
 
Figure 13. Target analogs of this work. 
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Results and Discussion 
1. Docking Studies 
The analogs were docked into the VDR(LBD), following a protocol developed in this 
research group, to predict their affinity for the vitamin D receptor.  
The structures of the docked analogues (A1-A4, E1-E4) are shown in Figure 14. 
 
Figure 14. Structure of the docked vitamin D analogs. 
The proposed analogs differ from one another by: the length of their side chain, the 
functional group at the end of the side chain and the configuration of the double bond. 
Firstly, the proposed analogs were built, using the three-dimensional structure of 
1,25D, obtained from the crystal calcitriol-VDR(LBD) complex (PDB code: 1DB1). 
Modifications to the analogs were carried out with the builder mode of Pymol and the 
editing tool provided by Chem3D software.  
Docking studies to predict the affinity of each analog for the VDR(LBD) were made 
using the Gold software (version Suite 5.2). A modified structure of VDR(LBD), with 
inclusion of hydrogens and missing gap regions, was used as the protein. The binding 
site of the protein was set automatically with a 10 Å radius. 
44 
FCUP | ICBAS | USC 
Results and Discussion  
 
Docking was performed in 25 independent genetic algorithm (GA) runs. In each run, a 
maximum of 125000 GA operations were performed in a single population of 100 
individuals. Default parameters were employed for hydrogen bonds (4.0 Å) and Van 
der Waals interactions (2.5 Å). ChemPLP was used as the scoring function and 
GoldScore was used as the re-scoring function.  
For each ligand, the three best solutions were normalized using the score of 1,25D as 
the reference value (100%). Figure 15 and Figure 16 represent the main interactions 
between the docked analogs and the amino acids of VDR. The relative score for each 
analog with respect to the natural hormone are shown in brackets.  
 
Figure 15. Ligand-VDR(LBD) interactions and relative scores for boronic acids analogs (A1-A4). 
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Figure 16. Ligand-VDR(LBD) interactions and relative scores for boronic esters analogs (E1-E4). 
Overall, the adopted conformations of the ligands vary little from that of calcitriol, as 
seen by the maintenance of the C3-OH and C1-OH hydrogen bonds with VDR for all 
analogs. Analogs with a boronic ester group at the side chain (Figure 16) present better 
scores when compared with the corresponding compounds with terminal boronic acid 
groups (Figure 15). 
Ligands A1 and A2 show lower score in comparison with the natural ligand (93% and 
92%, respectively). Ligand A1, despite the low score, shows stable hydrogen bonds 
through the OH groups with the amino acid residues in the binding pocket. Ligand A2 
appears to bind effectively with VDR(LBD), but the trans configuration seems to move 
the hydroxyl groups of the boronic acid apart from His-397. 
The side chains of both analogs A1 and A2 are far away from Val-418 (which is 
thought to be important to grant the transcriptional activity to the ligands that bind the 
receptor). We do not expect transcriptional activity for the analogs A1 and A2 because 
no interactions of the corresponding side chains with Val-418 are observed. 
46 
FCUP | ICBAS | USC 
Results and Discussion  
 
The side chains of A3 and A4 bind effectively with the His-305 and His-397 residues 
through the corresponding BOH groups. The verified lower scores for these analogs 
can be explained by different van der Walls interactions maintained between the 
analogs and the protein.  
In compound E1, one oxygen of Bpin interacts with His-305 by hydrogen bonds while 
no interactions of the same nature are observed with His-397. One methyl from Bpin 
also interacts with the amino acid Val-418. Therefore, based on these observations, 
this compound should induce transcription. 
Regarding compound E2, it binds effectively with both His-305 and His-397, by 
hydrogen bonding. Although the distance between the methyl group on the Bpin and 
Val-418 is slightly larger, this analog should bind well to the VDR receptor in vivo and 
induce transcription. 
Even though analog E3 does not interact with His-397 by hydrogen bonding, the methyl 
of its Bpin group is close to Val-418. Therefore, this compound might be an agonist. 
Analog E4 binds strongly by hydrogen bonds with both His-305 and His-397. In 
addition, the methyl of Bpin is close to Val-418. Therefore, this compound should 
behave as a superagonist. 
After analysing all the docked ligands in terms of score and interactions with the 
receptor amino acids, it is possible to designate the analogs A1, A4, E2 and E4 as the 
ones that should induce a stronger activity of VDR. 
In order to assess the validity of the in silico predictions, analog E4 was chosen to be 
synthesized, due to its score (107%) and interactions with the most relevant residues in 
the active centre of the VDR. Moreover, analog E4 would be a precursor of analog A4 
(94%) by removal of the pinacol ester in the side chain. The final goal is to characterize 
their biological profile in vivo. 
Figure 17 illustrates the superimposition of the structures obtained by docking for 
analogs A4 and E4 with the natural hormone in the active site of the VDR. 
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Figure 17. Superimposition of 1,25D with analogs A4 (left) and E4 (right) in the VDR active site. 
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2. General retrosynthetic route 
The synthetic plan for the proposed compounds is depicted in the Scheme 3. 
The boronic acid A4 would be obtained by deprotection of its boronic ester precursor 
E4. The triene system arises by a Pd-catalyzed ring closure on enol-triflate 2 and 
subsequent Suzuki−Miyaura coupling with boronate 1. Boronate 1 would derive from 
the known Inhoffen-Lythgoe diol 3, readily obtained by reductive ozonolysis of 
commercial vitamin D2.
[54] Enol-triflate 2 would be prepared from epoxide 4. 
 
Scheme 3. Retrosynthetic analysis of analogs A4 and E4. 
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3. Synthesis of boronate 1 (upper fragment) 
The synthesis of boronate 1 is depicted in Scheme 4 
 
Scheme 4. Synthesis of boronate 1 from Inhoffen-Lythgoe diol. 
3.1. Synthesis of alkene 10 
Starting from the Inhoffen-Lythgoe diol 3, the first step in the synthesis of boronic ester 
1 was the formation of alkene 10 (Scheme 4), following procedures previously 
developed in this research laboratory. 
Alcohol 3 was treated with iodine in the presence of triphenylphosphine and imidazole 
and provided iodide 5 in 90% yield. Treatment of 5 with potassium cyanide gave nitrile 
6 in 97% yield. Compound 6 was then protected with tert-butyldimethylsilyl chloride in 
the presence of 4-dimethylaminopyridine to give 7 in good yield. 
Reduction of the nitrile functionality with diisobutylaluminium hydride in 
dichlroromethane, followed by treatment of the resulting mixture with a solution of 
chloridric acid provided aldehyde 8 in 82% yield. 
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The resulting aldehyde 8 was then submitted to a Wittig reaction. In this reaction, 
treatment of compound 8 with the ylide Ph3P=CH2, generated by reaction of the 
phosphonium salt (Ph3PCH3)I with potassium tert-butoxide, originated olefin 9 in 90% 
yield.  
Scheme 5 shows the proposed mechanism for this Wittig-type reaction. 
 
Scheme 5. Proposed mechanism of the Wittig reaction for olefin 9. 
 
In this case, since the ylide possesses two hydrogens, there is no stereoselectivity and 
the final product is the olefin 9 in 90% yield. 
Figure 18 shows the most significant signals of the NMR spectra for compound 9. 
 
Figure 18. Characteristic NMR signals for compound 9. 
 
Desilylation of 9 with hydrogen fluoride in a mixture of dichloromethane/acetonitrile, 
provided alcohol 10 in 98% yield. 
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3.2. Preliminary experiments for the synthetic approach  
3.2.1. Preliminary experiments for the cross metathesis of compound E4 
Instead of continuing with the synthesis of boronate 1, it was decided to face the 
introduction of the boronate functionality at the side chain of 10. 
The intent of these experiments was to find reaction conditions to produce the boronic 
ester E4. Given the foreseeable difficulty in the synthesis, several conditions were 
tested using the CD bicycle of the vitamin as a simplified version of the full vitamin 
(Scheme 6, Table 1). 
 
Scheme 6. Preparation of boronic ester 11. 
 
In the first attempt to produce boronate 11 by cross metathesis, 2 equivalents of alkene 
10 were used, together with 1 eq. of vinyl boronic pinacol ester (pinBCH=CH2) in 
dichloromethane at room temperature, for 6 hours. The results were unsatisfactory, as 
only 40% of the desired product was obtained (Table 1, entry 1). In this reaction it was 
also observed the formation of vinyl boronic pinacol ester dimers, as well as the 
recovery of some initial substance 10.  
The use of pinBCH=CH2 in excess (2 eq) with the same reaction conditions gave 
boronate 11 in 95% yield (entry 2).[55] In this experiment, another modification made to 
the protocol was the addition of the Grubbs catalyst before adding the reactants. These 
modifications led to an increased yield and reduced the formation of by-products. 
Table 1. Tested conditions for olefin cross metathesis reaction. 
Entry 
Equivalents 
Solvent 
Temperature 
(ºC) 
Time 
(h) 
11 (Yield) 
10 
 
1 2 1 CH2Cl2 
20 6 
40% 
2 1 2 CH2Cl2 95% 
 
The trans configuration of the side chain double bond is proposed on the basis of a 
coupling constant JH = 17.9 between CH23-CH24. 
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3.2.2. Attempts to deprotect the pinacol ester group 
Once demonstrated the feasibility of the cross-metathesis reaction to introduce the 
trans-alkenyl boronate functionality, the transformation of the boronate functionality into 
the boronic acid group was also examined. 
The previously synthesized boronic ester 11 was protected by addition of TBSCl, to 
give compound 12 (Scheme 7).  
 
 
Scheme 7. Protection of the alcohol functional group of compound 11. 
The protected compound 12 was used to test the hypothesis that, with the use of 
deprotecting conditions, it was possible to obtain both, free OH groups as well as the 
boronic acid in the side chain. 
The tested conditions for the attempts to deprotect compound 12 are shown in  
Scheme 8 below. 
 
Scheme 8. Attempts to deprotect compound 12. 
 
Unfortunately, the attempts to deprotect the pin-moiety with TBAF or HF were 
unsuccessful. Treatment of 12 with TBAF in THF at room temperature for two days 
resulted in the recovery of the initial boronate 12. Removal of the TBS group under 
these reaction conditions is difficult due to its axial localization. Treatment of 12 with 
hydrogen fluoride in a mixture of MeCN and CH2Cl2, led to the obtention of the 
previously described alkene 10, as a result of protonation. 
As this point, it was decided to continue with the synthesis of analog E4, through 
boronate 1. 
FCUP | ICBAS | USC 
Results and Discussion 
53 
 
3.3. Synthesis of (E)-vinyl bromide 14 
Oxidation of alcohol 10 with Dess-Martin Periodinane (DMP).in dichloromethane 
produced ketone 13 in 98% yield. 
 
Scheme 9. Preparation of vinyl bromide 14 from alkene 10. 
The resulting ketone was submitted to Wittig chemistry using the ylide Ph3P=CHBr, 
prepared by reaction of phosphonium salt (Ph3PCH2Br)Br with potassium tert-butoxide, 
to give vinyl bromide 14 in 72% yield. 
The main 1H-NMR and 13C-NMR signals for compounds 13 and 14 are indicated in 
Figure 19 and Figure 20, respectively. 
 
 
Figure 19. Key NMR signals for compound 13. 
 
 
Figure 20. Key NMR signals for compound 14. 
The main problem in this olefination is the geometric selectivity, since the (E)-vinyl 
bromide 14 is required. Curiously, there is a noticeable E geometric selectivity in this 
reaction, contrary to the expected Z configuration. This observation can be explained in 
the light of two different theories, as shown by Trost.[56] On the one hand, dipole-dipole 
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interactions favour the E configuration and, on the other hand, a mechanism involving 
nucleophilic addition to a betaine may also be taken into account here.  
The result is an intermediate state that minimizes both dipole and eclipsing geometry, 
illustrated in Figure 21, below.[56] 
 
Figure 21. Proposed transition-state compound that leads to the (E)-vinyl bromide 14. 
 
3.4. Synthesis of boronate 1 
We next employed a Miyaura borylation reaction for the bromo-boron interchange. 
Thus, treatment of bromide 14 with bispinacolate diboron in the presence of  
[1,1′-Bis(diphenylphosphino)ferrocene]dichloropalladium(II) complexed with 
dichloromethane as the catalyst and triciclohexylphosphine in DMSO gave the desired 
boronate 1 in 84% yield. 
 
Scheme 10. Preparation of boronic ester 1 from vinyl bromide 14. 
The mechanism of Miyaura borylation comprises three steps. The first step is the 
oxidative addition of the Pd(0)-complex into the C-Br of the vinyl bromide 14. Next, 
trasmetallation allows the interchange of Br by a Bpin moiety into the palladium 
complex. In the last step, the reductive elimination affords the boronate 1 and the 
regeneration of the palladium(0) catalyst. 
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Figure 22 shows the most relevant NMR signals for compound 1. 
 
Figure 22. Key NMR signals for compound 1. 
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4. Synthesis of enol-triflate 2 (bottom fragment) 
The next step in the synthesis of the desired analog E4 was the preparation of  
enol-triflate 2 (Scheme 11). 
 
Scheme 11. Preparation of enol-triflate 16 from epoxide 4. 
 
Treatment of epoxide 4 with periodic acid in ether afforded the dicarbonilic compound 
15, which was converted into dibromide 16 by treatment with carbon tetrabromide in 
the presence of PPh3 and zinc.
[57] Finally, dibromide 16 was treated with LDA to form 
the triple bond and the enolate, which was trapped with Comins’ reagent  
[N-(5-Chloro-2-pyridyl)bis(trifluoromethanesulfonimide)][58] to produce the desired enol-
triflate 2. 
Figure 23 shows the characteristic NMR signals for enol-triflate 2. 
 
Figure 23. Key NMR signals for compound 2. 
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5. Synthesis of 17 
With boronic ester 1 and enol-triflate 2 in hands, the preparation of compound 17 was 
faced. Pd-catalyzed ring closure of enol-triflate 2 and subsequent Suzuki−Miyaura 
coupling with boronate 1, in the presence of aqueous K3PO4, afforded, after desilylation 
with TBAF, the desired vitamin D analog 17 in 89% yield (Scheme 12). 
 
 
Scheme 12. Preparation of compound 17 from boronic ester 1 and enol-triflate 2. 
Scheme 13 illustrates the proposed mechanism for this Pd(0)-catalysed convergent 
tandem cyclization Suzuki cross-coupling between enol-triflate 2 and boronate 1. The 
use of K3PO4 activates boronate 1, favouring the transmetallation step. 
 
Scheme 13. Proposed mechanism for the Suzuki cross-coupling reaction between enol-triflate 2 and boronic ester 1. 
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6. Synthesis of boronic ester E4 
In the last step, the synthesis of the target analog E4 was accomplished using the 
cross metathesis reaction previously described in this work (Scheme 14). 
 
 
Scheme 14. Preparation of analog E4 from alkene 17. 
 
Treatment of alkene 17 (1 equiv) with vinyl boronic pinacol ester (pinBCH=CH2) in the 
presence of the second generation Grubbs catalyst (2 equiv) gave the target analog E4 
in 74% yield. 
Scheme 15 shows the proposed reaction mechanism for this reaction. 
 
Scheme 15. Proposed mechanism for the olefin cross metathesis reaction. 
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Figure 24 shows the 1H-NMR spectrum of analog E4. 
 
Figure 24. 1H-NMR spectrum (400 MHz, CDCl3) of analog E4 and most relevant signals 
 
The characteristic signals belonging to the A ring and triene system are observed.  
A singlet peak for the methyl groups of the Bpin moiety at 1.27 ppm is also identified.  
The trans configuration of the side chain double bond is confirmed by a coupling 
constant of JH-H = 17.9 Hz. 
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Conclusions 
Through docking calculations, it was possible to test eight vitamin D analogs (A1, A2, 
A3, A4, E1, E2, E3, E4) in terms of their affinity to the VRD(LBD). These in silico 
studies indicated that analogs A4 and E4 adopted a similar conformation to the natural 
hormone 1,25D in the binding pocket. Both analogs showed similar or even higher 
affinities to VDR in comparison with the native hormone 1,25D and, therefore, should 
behave as agonists of the VDR. 
Although the plan was to synthesize both analogs A4 and E4, it was only possible to 
obtain the target compound E4. 
The synthesis started from the individual formation of both the upper and bottom 
fragments of the vitamin D. These fragments were put together through a Suzuki 
Miyaura Pd-catalyzed tandem carbocyclization process. In a last step and by an olefin 
metathesis, it was possible to obtain the target compound E4 with a global yield of 14% 
in twelve steps. 
Analog E4 is about to undergo both in vitro and in vivo biological assays, to test the 
biological effects of this analog in different cell lines, as well as its role in the regulation 
of serum calcium levels in mice. 
This work allowed the development of a new methodology for the preparation of 
vitamin D analogs containing a boronate group that could have interesting biological 
properties and promising applications in drug research.  
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Experimental Procedures 
1. General Procedures 
All reactions including oxygen or moisture-sensitive compounds or mixtures were 
carried out under dry argon atmosphere (Alphagaz-1 Argon). The used glassware was 
dried in a 150 ºC oven and heat or flame-dried and cooled under argon pressure 
immediately before use. Standard syringe/septa techniques were employed. 
In low-temperature experiments, water/ice baths were used in reactions carried out at  
0 ºC. Methanol baths cooled with a CRYOCOOL immersion cooler, provided with a 
temperature regulator were employed in experiments at negative temperatures. 
In high-temperature experiments, silicon baths were used, provided with a contact 
thermometer directly in the bath. All indicated temperatures refer to the external bath 
temperatures employed, unless stated otherwise.   
All dry solvents were distilled under argon pressure immediately prior to use. Et2O, THF 
and toluene were distilled from Na/benzophenone and CH2Cl2 was distilled from P2O5. 
DMSO was distilled from CaH2 under vacuum and then stored on molecular sieves of  
4 Å. DMF was dried with 4 Å molecular sieves.  
Commercial solutions of nBuLi (in hexanes) were titrated with N-benzylbenzamide 
before use. 
The progress of the reactions was followed by thin layer chromatography (TLC) using 
aluminum plates with a silca gel layer Merck 60 (0.2 mm thickness). In the revealing 
process, the chromatograms, were visualized under UV light (254 nm) and then 
immersed in solutions of ceric ammonium molybdate or p-anisaldehyde. 
Reactions that made use of ultrasounds were carried out in a JP Selecta Ultrasons.  
Organic extracts were dried over anhydrous Na2SO4, filtered and concentrated using a 
rotary evaporator at reduced pressure (20-30 mmHg). 
During flash column chromatography, Merck silica gel 60 (230-400 mesh) was used. 
Solvents used in the mobile phase such as hexanes, EtOAc or CH2Cl2 were distilled 
prior to their use. 
Compound’s HPLC purifications were performed in a Shimadzu liquid preparative 
chromatograph model LC-8A with an absorbance detector TSP-UV1. The column used 
with this equipment was a HPLC column Phenomenex® Luna® 5 µm with a Silica (2) 
stationary phase (5 µm particle size, 100 Å pore size, 250 mm length, 10 mm internal 
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diameter). Yields refer to chromatographically purified compounds unless otherwise 
specified. 
The NMR spectra were registered in Brucker DPX-250 (250 MHz for 1H, 63 MHz for 
13C) and Varian Inova-400 (400 MHz for 1H) spectrometers, from RMN services at 
Universidad de Santiago de Compostela. The spectra were performed using CDCl3 as 
a solvent. Chemical shifts are reported on the δ scale (ppm) downfield from 
tetramethylsilane (δ = 0.0 ppm) using the residual solvent signal at δ = 7.26 ppm (1H, s, 
CDCl3) or δ = 77.0 ppm (13C, t, CDCl3). Coupling constants (J) are reported in the Hz 
scale.  
High resolution mass spectra (HRMS) were performed in a Micromass Instruments 
Autospec (EI+, CI+), a Thermo Finningan MAT95XP (EI+) and an Applied Biosystems 
QSTAR Elite spectrometers (ESI+). IR spectra were recorded in a silicon disc on Bruker 
IFS 66V and VECTOR 22 FT-IR spectrometers. 
The references and respective distributor for each of the reactants used in this work 
are presented below. 
B2Pin2: Aldrich, Ref. 47,329-4 
CBr4: Aldrich, Ref. C11081 
DIBAL-H: Aldrich, Ref. 214973 
DMAP: Fluka, Ref. 29224 
Grubbs Catalyst™ 2nd Generation: Aldrich, Ref. 569747 
H5IO6: Fluka, Ref. 77310 
HF, Acros: Ref.423805000 
I2: Fluka, Ref. 56750 
Imidazole: Fluka, Ref. 56750 
K3PO4·3H2O: Aldrich, Ref. P5629 
KOAc: Merck, Ref. 104820 
KOtBu: Fluka, Ref. 60100  
Na2S2O3: Quimipur, w/o Ref. 
Na2SO4: Quimipur, w/o Ref. 
NaHCO3: Quimipur, w/o Ref. 
nBuLi: Acros, 18127 
NH4Cl: Quimipur, w/o Ref. 
PCy3: Aldrich, Ref. 261971 
PdCl2(dppf)·CH2Cl2: Aldrich, Ref. 379670 
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PdCl2(PPh3)2: Fluka, Ref. 15253 
PPh3: Aldrich, Ref. T84409 
Silica Gel (SiO2): Merck, Ref. 1.09385.2500 
TBAF: Aldrich, Ref. 216143 
TBSCl: ABCR, Ref. AB110655 
Vinylboronic acid pinacol ester: Acros, Ref. 395530 
 
The compounds were named and numbered following the systematic nomenclature 
proposed by IUPAC using Chemdraw® computer software. In all the synthesized 
molecules, steroidal nomenclature and numbering was employed for the RMN analysis. 
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(1R,3aR,4S,7aR)-1-((S)-1-Iodopropan-2-yl)-7a-methyloctahydro-1H-inden-4-ol 
 
Triphenylphosphine (679 mg, 2.59 mmol, 1.1 equiv) and Imidazole (480 mg,  
7.05 mmol, 3 equiv) were successively added to a solution of 3 (500 mg, 2.35 mmol,  
1 equiv) in dry THF (20 mL). After cooling at -20 ºC, I2 was added. The mixture was 
stirred at rt for 2h. The reaction was quenched with a saturated solution of NaHCO3  
(20 mL) and Na2S2O3 (20 mL). The mixture was extracted with CH2Cl2 (3×15 mL). The 
combined organic extracts were dried, filtered and concentrated in vacuo. The residue 
was purified by flash column chromatography (SiO2, 2.5×5 cm, 20% EtOAc/hexanes) to 
give 5 [722 mg, 90%, Rf = 0.54 (30% EtOAc-hexanes), white solid]. 
1H NMR (250 MHz, CDCl3) δ 4.06 (s, 1H, H-8), 3.30 (dd, J = 9.5, 1.9 Hz, 1H, H-22), 
3.16 (dd, J = 9.4, 4.5 Hz, 1H, H-22), 1.98 – 1.73 (m, 4H), 1.61 – 1.29 (m, 5H),  
1.25 – 1.08 (m, 4H), 1.00 – 0.94 (m, 6H, Me-18, Me-21). 13C NMR (63 MHz, CDCl3) δ 
69.06 (CH, C8), 55.79 (CH), 52.23 (CH), 41.74 (C, C-13), 40.01 (CH2), 36.25 (CH), 
33.46 (CH2), 26.45 (CH2), 22.31 (CH2), 21.24 (CH2), 20.59 (CH3, C-21), 17.30 (CH2), 
14.30 (CH3, C-18). 
(R)-3-((1R,3aR,4S,7aR)-4-Hydroxy-7a-methyloctahydro-1H-inden-1-
yl)butanenitrile 
 
Potassium cyanide (365 mg, 5.60 mmol, 2.5 equiv) was added to a solution of 5  
(722 mg, 2.24 mmol, 1 equiv) in DMSO (20 mL). The mixture was stirred at  
85 ºC for 2 h, and then cooled to rt. The reaction was quenched with H2O (40 mL). 
Saturated NaCl (10 mL) was added and the mixture was extracted with 10% 
EtOAc/hexanes (4×10 mL). The combined organic phases were dried with Na2SO4, 
filtered and concentrated in vacuo. The residue was purified by flash column 
chromatography (SiO2, 3×5 cm, 20% EtOAc/hexanes) to give 6 [483 mg, 97%,  
Rf = 0.37 (30% EtOAc-hexanes), white solid]. 
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1H NMR (250 MHz, CDCl3) δ 4.06 (s, 1H, H-8), 2.36 – 2.19 (m, 2H, H-22), 1.97 – 1.75 
(m, 5H), 1.57 – 1.36 (m, 6H), 1.28 – 1.17 (m, 3H), 1.12 (d, J = 6.6 Hz, 3H, Me -21), 
0.93 (s, 3H, Me-18). 13C NMR (63 MHz, CDCl3) δ 118.84 (C, C≡N), 68.81 (CH, C-8), 
55.09 (CH), 52.29 (CH), 41.82 (C, C-13), 39.93 (CH2), 33.42 (CH2), 32.94 (CH), 26.95 
(CH2), 24.56 (CH2), 22.30 (CH2), 19.08 (CH3, C-21), 17.22 (CH2), 13.54 (CH3, C-18). 
(R)-3-((1R,3aR,4S,7aR)-4-((tert-Butyldimethylsilyl)oxy)-7a-methyloctahydro-1H-
inden-1-yl)butanenitrile 
 
Imidazole (365 mg, 5.36 mmol, 2.1 equiv), DMAP (94 mg, 0.77 mmol, 0.3 equiv) and 
TBSCl (498 mg, 3.32 mmol, 1.3 equiv) were successively added to a solution of 6  
(565 mg, 2.55 mmol, 1 equiv) in DMF (20 mL). The mixture was stirred at rt for 10 h. 
The reaction was quenched with a saturated solution of NaCl (20 mL). The mixture was 
extracted with hexanes (3×15 mL). The combined organic extracts were dried, filtered 
and concentrated in vacuo. The residue was purified by flash column chromatography 
(SiO2, 3×5 cm, 5% EtOAc/hexanes) to yield 7 [746 mg, 87%, Rf = 0.85  
(30% EtOAc/hexanes), white solid]. 
1H NMR (250 MHz, CDCl3) δ 3.96 (s, 1H, H-8), 2.29 (dd, J = 16.6, 3.9 Hz, 1H, H-22), 
2.16 (dd, J = 16.7, 6.8 Hz, 1H, H-22), 1.90 – 1.51 (m, 6H), 1.41 – 1.12 (m, 7H), 1.08 (d, 
J = 6.6 Hz, 3H, Me-21), 0.88 (s, 3H, Me-18), 0.83 (d, J = 0.9 Hz, 9H, tBu-Si), -0.05 (d,  
J = 4.1 Hz, 6H, 2×Me-Si). 13C NMR (63 MHz, CDCl3) δ 118.8 (C, C≡N), 69.1 (CH, C-8), 
55.2 (CH), 52.7 (CH), 42.0 (C, C-13), 40.2 (CH2), 34.1 (CH2), 33.0 (CH), 27.1 (CH2), 
25.7 (3×CH3, 
tBu-Si), 24.5 (CH2), 22.8 (CH2), 19.1 (CH3, C-21), 17.9 (C, Si), 17.40 
(CH2), 13.7 (CH3, C-18), -5.0 (CH3, Me-Si), -5.3 (CH3, Me-Si). HRMS (ESI-TOF)+: 
[M+Na]+ calcd for C14H23NONa 244.1671, found 244.1679. 
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(R)-3-((1R,3aR,4S,7aR)-4-((tert-Butyldimethylsilyl)oxy)-7a-methyloctahydro-1H-
inden-1-yl)butanal 
 
DIBAL-H (1.0 M in hexanes, 4.41 mL, 4.41 mmol) was added dropwise to a solution of 
7 (740 mg, 2.20 mmol, 1 equiv) in CH2Cl2 (20 mL) cooled at -10 ºC and stirred for 1h. 
The reaction was quenched by pouring the mixture into an aqueous solution of HCl 
(10%, 50 mL) and CH2Cl2 (50 mL) and then the mixture was stirred at 0 ºC for 2 h. The 
mixture was extracted with CH2Cl2 (3×20 mL). The organic phase was washed with 
saturated solutions of NaHCO3 (30 mL) and NaCl (30 mL). The combined organic 
extracts were dried, filtered, and concentrated in vacuo. The crude product was purified 
by flash chromatography (SiO2, 3×5 cm, 5% EtOAc/hexanes) to yield 8 [613 mg, 82%, 
Rf = 0.48 (5% EtOAc/hexanes), yellow oil]. 
1H NMR (250 MHz, CDCl3) δ 9.70 (dd, J = 3.4, 1.4 Hz, 1H, CHO), 3.96 (s, 1H, H-8), 
2.41 (d, J = 14.0 Hz, 1H), 2.16 – 1.85 (m, 3H), 1.79 – 1.51 (m, 4H), 1.39 – 1.09 (m, 
7H), 0.95 (d, J = 6.4 Hz, 3H, Me-21), 0.92 (s, 3H, Me-18), 0.85 (s, 9H, tBu-Si), -0.04 (d, 
J = 3.6 Hz, 6H, 2×Me-Si). 13C NMR (63 MHz, CDCl3) δ 203.5 (CH, CHO), 69.3 (CH,  
C-8), 56.5 (CH), 53.0 (CH), 50.8 (CH2), 42.3 (C, C-13), 40.5 (CH2), 34.31 (CH2), 31.24 
(CH), 27.54 (CH2), 25.78 (3×CH3, 
tBu-Si), 23.0 (CH2), 20.0 (CH3, C-21), 18.0 (C, Si), 
17.6 (CH2), 13.7 (CH3, C-18), -4.8 (CH3, Me-Si), -5.2 (CH3, Me-Si). 
tert-Butyldimethyl(((1R,3aR,4S,7aR)-7a-methyl-1-((R)-pent-4-en-2-yl)octahydro-
1H-inden-4-yl)oxy)silane 
 
A suspension of (Ph3PCH3)I (2.00 g, 4.95 mmol, 5 equiv) in dry THF (15 mL) was 
sonicated for 30 min. After cooling the suspension at 0 ºC, an aqueous solution of 
KOtBu (8.87 mL, 4.85 mmol, 1 M, 4.9 equiv) was added, dropwise.  
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After 1.5 h of stirring at 0 ºC, the mixture was warmed to rt and a solution of 8  
(335 mg, 0,99 mmol, 1 equiv) in THF (5 mL) was added. The resulting mixture was 
stirred at rt for 2 h. The reaction was quenched with a saturated NH4Cl solution (2 mL) 
and filtered through a layer of silica gel. The silica was washed with hexanes (40 mL) 
and the filtrate was concentrated in vacuo. The residue was purified by flash 
chromatography (SiO2, 2.5×5 cm, hexanes) to give 9 [299 mg, 90%, Rf = 0.96  
(5% EtOAc/hexanes), [𝛼]𝐷
20 = 38.2 (c = 1, CHCl3), yellow oil]. 
1H NMR (250 MHz, CDCl3) δ 5.84 – 5.62 (m, 1H, H-23), 4.95 (d, J = 13.3 Hz, 2H,  
H-24), 3.97 (s, 1H, H-8), 2.15 (d, J = 12.5 Hz, 1H), 1.99 – 1.44 (m, 7H), 1.40 – 1.19 (m, 
5H), 1.12 – 0.95 (m, 2H), 0.88 (d, J = 7.2 Hz, 15H, Me-21, Me-18, tBu-Si), -0.02 (d,  
J = 2.8 Hz, 6H, 2×Me-Si). 13C NMR (63 MHz, CDCl3) δ 137.5 (CH, C-23), 115.57 (CH2,  
C-24), 69.47 (CH, C-8), 56.4 (CH), 53.0 (CH), 42.1 (C, C-13), 40.6 (CH2), 40.5 (CH2), 
35.3 (CH), 34.5 (CH2), 27.3 (CH2), 25.8 (3×CH3, 
tBu-Si), 23.1 (CH2), 18.6 (CH3, C-21), 
18.0 (C, C-Si), 17.7 (CH2), 13.8 (CH3, C-18), -4.8 (CH3, Me-Si), -5.2 (CH3, Me-Si). 
HRMS (EI): [M]+ calcd for C21H40OSi 336.2843, found 336.2847. 
(1R,3aR,4S,7aR)-7a-Methyl-1-((R)-pent-4-en-2-yl)octahydro-1H-inden-4-ol 
 
HF (15 drops, 48%) was added to a solution of 9 (460 mg, 1.37 mmol) in CH2Cl2 (6 mL) 
and CH3CN (12 mL). The reaction mixture was stirred at rt during 4 h. The reaction was 
quenched by slowly pouring the mixture into a saturated solution of NaHCO3 (50 mL). 
The mixture was extracted with CH2Cl2 (3×20 mL). The combined organic extracts 
were dried, filtered and concentrated in vacuo. The resulting residue was purified by 
flash chromatography (SiO2, 2.5×5 cm, 5-10 % EtOAc/hexanes) to give 10 [298 mg, 
98%, Rf = 0.22 (10% EtOAc/hexanes), [𝛼]𝐷
20 = 29.8 (c = 0.5, CHCl3), yellow oil]. 
1H NMR (250 MHz, CDCl3) δ 5.81 – 5.62 (m, 1H, H-23), 4.93 (d, J = 12.6 Hz, 2H,  
H-24), 4.02 (s, 1H, H-8), 2.19 – 2.06 (m, 1H), 2.00 – 1.89 (m, 1H), 1.86 – 1.65 (m, 4H), 
1.52 – 1.22 (m, 8H), 1.16 – 1.00 (m, 2H), 0.89 (s, 3H, Me-18), 0.86 (d, J = 8.0 Hz, 3H, 
Me-21). 13C NMR (63 MHz, CDCl3) δ 137.2 (CH, C-23), 115.7 (CH2, C-24), 69.2  
(CH, C8), 56.1 (CH), 52.5 (CH), 41.8 (C, C13), 40.4 (CH2), 40.2 (CH2) 35.2 (CH), 33.52 
(CH2), 27.0 (CH2), 22.5 (CH2), 18.4 (CH3, Me-21), 17.4 (CH2), 13.5 (CH3, Me-18). 
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(1R,3aR,7aR)-7a-Methyl-1-((R)-pent-4-en-2-yl)octahydro-4H-inden-4-one 
 
Dess-Martin Periodinane (626 mg, 1.47 mmol, 1.1 equiv) was added to a solution of 10 
(298 mg, 1.34 mmol, 1 equiv) in dry CH2Cl2 (10 mL). After stirring at rt for 2 h, the 
mixture was concentrated in vacuo to remove excess CH2Cl2. The residue was then 
purified by flash chromatography (SiO2, 3×4 cm, hexanes) to give 13 [290 mg, 98%,  
Rf = 0.65 (20% EtOAc/hexanes), [𝛼]𝐷
20 = -19.8 (c = 1, CHCl3), yellow oil]. 
1H NMR (250 MHz, CDCl3) δ 5.80 – 5.56 (m, 1H, H-23), 4.95 (d, J = 12.6 Hz, 2H,  
H-24), 2.40 (dd, J = 11.5, 7.5 Hz, 1H), 2.27 – 1.98 (m, 4H), 1.97 – 1.62 (m, 5H),  
1.57 – 1.24 (m, 5H), 0.91 (d, J = 6.1 Hz, 3H, Me-21), 0.59 (s, 3H, Me-18). 13C NMR  
(63 MHz, CDCl3) δ 211.9 (C, C-8), 136.7 (CH, C-23), 116.0 (CH2, C-24), 61.8 (CH), 
56.1 (CH), 49.8 (C, C-13), 40.9 (CH2), 40.3 (CH2), 38.8 (CH2), 35.4 (CH), 27.4 (CH2), 
24.0 (CH2), 19.0 (CH2), 18.6 (CH3, Me-21), 12.4 (CH3, Me-18). 
(1R,3aR,7aR,E)-4-(Bromomethylene)-7a-methyl-1-((R)-pent-4-en-2-yl)octahydro-
1H-indene 
 
A suspension of (Ph3PCH2Br)Br (4.018 g, 9.21 mmol, 7 equiv) in toluene (20 mL) was 
sonicated for 30 min. The suspension was cooled to -20 ºC and a solution of KOtBu 
(9.08 mL, 9.08 mmol, 1M, 6.9 equiv) was added. After 2 h, an aqueous solution of 13  
(290 mg, 1.32 mmol, 1 equiv) in toluene (10 mL) was added. The resulting mixture was 
stirred during 2 h at -20 ºC. The reaction was quenched with NH4Cl (2 mL) and filtered 
through a layer of silica gel. The silica was washed with MTBE (40 mL) and the 
combined filtrate was concentrated.  
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The residue was then purified by flash chromatography (SiO2, 3×5 cm, hexanes) to 
give 14 [246 mg, 72%, Rf = 0.91 (5% EtOAc/hexanes), [𝛼]𝐷
20 = 84.0 (c = 1, CHCl3), 
yellow oil]. 
1H NMR (250 MHz, CDCl3) δ 5.89 – 5.67 (m, 1H, H-23), 5.65 (s, 1H, H-7), 4.99 (d,  
J = 13.6 Hz, 2H, H-24), 2.87 (dd, J = 11.0, 2.5 Hz, 1H), 2.24 – 2.13 (m, 1H),  
2.03 – 1.80 (m, 4H), 1.69 – 1.44 (m, 6H), 1.36 – 1.23 (m, 3H), 0.94 (d, J = 6.5 Hz, 3H, 
Me-21), 0.57 (s, 3H, Me-18). 13C NMR (63 MHz, CDCl3) δ 145.0 (C-8), 137.0 (CH,  
C-23), 115.9 (CH2, C24), 97.4 (CH, C-7), 55.8 (CH), 55.3 (CH), 45.4 (C, C-13), 40.5 
(CH), 39.7 (CH), 35.9 (CH), 31.0 (CH2), 27.5 (CH2), 22.5 (CH2), 22.0 (CH2), 18.7  
(CH3, Me-21), 11.8 (CH3, Me-18). HRMS (EI): [M]+ calcd for C16H25Br 296.1134, found 
296.1135. 
4,4,5,5-Tetramethyl-2-(((1R,3aS,7aR,E)-7a-methyl-1-((R)-pent-4-en-2-yl)octahydro-
4H-inden-4-ylidene)methyl)-1,3,2-dioxaborolane 
 
PdCl2(dppf).CH2Cl2 (8 mg, 0.01 mmol, 0.03 equiv) and PCy3 (6 mg, 0.02 mmol,  
0.03 equiv) were dissolved in dry DMSO (1 mL). The solution was stirred for 30 min. A 
solution of 14 (102 mg, 0.34 mmol, 1 equiv) in DMSO (2 mL) was then added through 
cannula. B2pin2 (173 mg, 0.68 mmol, 2 equiv) and KOAc (100 mg, 1.02 mmol, 3 equiv) 
were added to the reaction. The reaction mixture was stirred at 80 ºC for 2 h. The 
reaction was quenched with H2O (20 mL) and the mixture was extracted with MTBE 
(4×15 mL). The combined organic extracts were dried, filtered and concentrated. The 
residue was purified by flash chromatography (SiO2, 2×5.5 cm, 0-5% EtOAc-hexanes) 
to give 1 [93 mg, 68%, Rf = 0.54 (5% EtOAc-hexanes), [𝛼]𝐷
20 = 66.7 (c = 1, CHCl3), 
yellow oil]. 
1H NMR (400 MHz, CDCl3) δ 5.73 (s, 1H, H-23), 4.95 (d, J = 13.4 Hz, 2H, H-24), 4.88 
(s, 1H, H-7), 3.14 (d, J = 12.9 Hz, 1H), 2.15 (d, J = 11.0 Hz, 1H), 2.04 – 1.41 (m, 13H), 
1.23 (s, 12H, 4×CH3COB), 0.90 (s, 3H, Me-21), 0.53 (s, 3H, Me-18). 13C NMR (63 MHz, 
CDCl3) δ 166.2 (C, C-8), 137.3 (CH, C-23), 115.7 (CH2, C-24), 82.5 (C, 2×COB), 57.9 
(CH), 56.3 (CH), 46.2 (C, C-13), 40.5 (CH2), 40.3 (CH2), 36.0 (CH), 33.2 (CH2), 27.4 
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(CH2), 24.9 (CH3, 2×COB), 24.8 (CH3, 2×COB), 24.3 (CH2), 22.3 (CH2), 18.7 (CH3,  
Me-21), 12.1 (CH3, Me-18). HRMS (ESI-TOF)+: [M+Na]+ calcd for C22H37BO2Na 
367.2778, found 367.2771. 
(1R,3S,Z)-5-(2-((1R,3aS,7aR,E)-7a-Methyl-1-((R)-pent-4-en-2-yl)octahydro-4H-
inden-4-ylidene)ethylidene)-4-methylenecyclohexane-1,3-diol  
 
An aqueous solution of K3PO4 (2.0 mL, 2M) was added to a solution of 1 (93 mg,  
0.27 mmol, 1 equiv) and 2 (167 mg, 0.32 mmol, 1.2 equiv) in dry THF (2 mL). Then, 
PdCl2(PPh3)2 (9.2 mg, 0.01 mmol, 0.05 equiv) was added. The mixture was vigorously 
stirred at rt for 4 h and protected from light. The reaction was quenched with H2O  
(20 mL) and the mixture was extracted with MTBE (4×15 mL). The resulting combined 
organic extracts were dried, filtered and concentrated. The residue was then dissolved 
in THF and a solution of TBAF in THF (1.54 mL, 1.54 mmol, 1M, 5 equiv) was added. 
After 20 h of stirring at rt, the reaction was quenched with H2O (20 mL). The mixture 
was extracted with EtOAc (3×15 mL). The combined organic extracts were dried, 
filtered and concentrated in vacuo. The residue was purified by flash column 
chromatography (SiO2, 1.5×6 cm, 50% EtOAc/hexanes) to yield 17 [86 mg, 89%,  
Rf = 0.2 (40 % EtOAc/hexanes), [𝛼]𝐷
20 = 27.6 (c = 0.5, CHCl3), yellow oil]. 
1H NMR (400 MHz, CDCl3) δ 6.38 (d, J = 11.2 Hz, 1H, H-6), 6.02 (d, J = 11.3 Hz, 1H, 
H-7), 5.83 – 5.71 (m, 1H, H-23), 5.33 (s, 1H, H-19), 4.99 (d, J = 11.8 Hz, 3H, H-19,  
H-24), 4.43 (dd, J = 7.4, 4.3 Hz, 1H, H-1), 4.26 – 4.20 (m, 1H, H-3), 2.82 (dd, J = 11.9, 
3.6 Hz, 1H), 2.59 (dd, J = 13.3, 2.9 Hz, 1H), 2.31 (dd, J = 13.4, 6.5 Hz, 1H), 2.18 (d,  
J = 13.5 Hz, 1H), 2.03 – 1.85 (m, 6H), 1.67 (d, J = 10.8 Hz, 5H), 1.53 – 1.44 (m, 4H), 
1.34 – 1.25 (m, 4H), 0.93 (d, J = 6.6 Hz, 3H, Me-21), 0.55 (s, 3H, Me-18).  
13C NMR (63 MHz, CDCl3) δ 147.6 (C, C-10), 143.2 (C, C-8), 137.3 (CH, C-23), 132.9 
(C, C-5), 125.0 (CH, C-6), 117,0 (CH, C-7), 115,8 (CH2, C-24) 111.8 (CH2, C-19), 70.8 
(CH, C-OH), 66.8 (CH, C-OH), 56.3 (CH), 56.0 (CH), 45.9 (C, C-13), 45.2 (CH2), 42.8 
(CH2), 40.5 (CH2), 40.3 (CH2), 36.1 (CH), 29.1 (CH2), 27.6 (CH2), 23.6 (CH2),  
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22.3 (CH2), 18.7 (CH3, Me-21), 12.0 (CH3, Me-18). HRMS (ESI-TOF)+: [M+Na]+ calcd 
for C24H36O2Na 379.2608, found 379.2616. 
(1R,3S,Z)-5-(2-((1R,3aS,7aR,E)-7a-methyl-1-((R,E)-5-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)pent-4-en-2-yl)octahydro-4H-inden-4-ylidene)ethylidene)-4-
methylenecyclohexane-1,3-diol 
 
Vinylboronic acid pinacol ester (22 mg, 0.14 mmol, 2 equiv) was added to a mixture of 
compound 17 (25 mg, 0.07 mmol, 1 equiv) and 2nd generation Grubbs Catalyst™  
(2.97 mg, 0.0035 mmol, 0.05 equiv) in dry CH2Cl2 (2 mL). The resulting mixture was 
then heated at 46 ºC and stirred for 6 h. The mixture was cooled to rt and then 
concentrated in vacuo to remove excess CH2Cl2. The residue was purified by flash 
chromatography (SiO2, 2×4 cm, 70% EtOAc-hexanes) to give E4 [25 mg, 74%,  
Rf = 0.97 (70% EtOAc-hexanes), [𝛼]𝐷
20 = 14.8 (c = 0.7, CHCl3), yellow oil]. 
1H NMR (400 MHz, CDCl3) δ 6.59 (ddd, J = 17.8, 7.9, 5.9 Hz, 1H, H-23), 6.37 (d,  
J = 11.2 Hz, 1H, H-6), 6.01 (d, J = 11.2 Hz, 1H, H-7), 5.42 (d, J = 17.9 Hz, 1H, H-24), 
5.32 (s, 1H, H-19), 5.00 (s, 1H, H-19), 4.43 (dd, J = 7.6, 4.3 Hz, 1H, H-1), 4.22 (dt,  
J = 9.9, 3.3 Hz, 1H, H-3), 2.82 (d, J = 12.7 Hz, 1H), 2.60 (d, J = 10.5 Hz, 1H), 2.31 (dd, 
J = 13.4, 6.7 Hz, 2H), 2.05 – 1.86 (m, 7H), 1.68 – 1.45 (m, 10H), 1.27 (s, 12H, 
4×CH3COB), 0.93 (d, J = 6.5 Hz, 3H, Me-21), 0.54 (s, 3H, Me-18). 13C NMR (63 MHz, 
CDCl3) δ 153.3 (CH, C-23), 147.6 (C, C-10), 143.1 (C, C-8), 132.8 (C, C-5), 124.9 (CH, 
C-6), 117.0 (CH, C-7), 111.8 (CH2, C-19), 83.0 (C, COB), 70.8 (CH), 66.8 (CH), 56.2 
(CH), 56.1 (CH), 45.9 (C, C-13), 45.2 (CH2) 42.8 (CH2), 40.3 (CH2), 35.9 (CH), 29.0 
(CH2), 27.6 (CH2), 24.8 (CH3, 4×COB), 23.5 (CH2), 22.2 (CH2), 19.1 (CH3, C-21), 12.0 
(CH3, C-18). HRMS (ESI-TOF)+: [M+H]+ calcd for C30H48BO4 483.3640, found 
483.3638.
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Supplementary Information 
1. NMR Spectra 
1H NMR (250 MHz, CDCl3) δ 4.06 (s, 1H, H-8), 3.30 (dd, J = 9.5, 
1.9 Hz, 1H, H-22), 3.16 (dd, J = 9.4, 4.5 Hz, 1H, H-22),  
1.98 – 1.73 (m, 4H), 1.61 – 1.29 (m, 5H), 1.25 – 1.08 (m, 4H), 
1.00 – 0.94 (m, 6H, Me-18, Me-21). 
 
13C NMR (63 MHz, CDCl3) δ 69.06 (CH, C8), 55.79 (CH), 52.23 (CH), 41.74 (C, C-13), 
40.01 (CH2), 36.25 (CH), 33.46 (CH2), 26.45 (CH2), 22.31 (CH2), 21.24 (CH2), 20.59 
(CH3, C-21), 17.30 (CH2), 14.30 (CH3, C-18).  
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1H NMR (250 MHz, CDCl3) δ 4.06 (s, 1H, H-8), 2.36 – 2.19  
(m, 2H, H-22), 1.97 – 1.75 (m, 5H), 1.57 – 1.36 (m, 6H), 1.28 – 
1.17 (m, 3H), 1.12 (d, J = 6.6 Hz, 3H, Me -21), 0.93 (s, 3H, Me-
18). 
 
13C NMR (63 MHz, CDCl3) δ 118.84 (C, C≡N), 68.81 (CH, C-8), 55.09 (CH), 52.29 
(CH), 41.82 (C, C-13), 39.93 (CH2), 33.42 (CH2), 32.94 (CH), 26.95 (CH2), 24.56 (CH2), 
22.30 (CH2), 19.08 (CH3, C-21), 17.22 (CH2), 13.54 (CH3, C-18). 
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1H NMR (250 MHz, CDCl3) δ 3.96 (s, 1H, H-8), 2.29 (dd,  
J = 16.6, 3.9 Hz, 1H, H-22), 2.16 (dd, J = 16.7, 6.8 Hz, 1H,  
H-22), 1.90 – 1.51 (m, 6H), 1.41 – 1.12 (m, 7H), 1.08 (d,  
J = 6.6 Hz, 3H, Me-21), 0.88 (s, 3H, Me-18), 0.83 (d, J = 0.9 Hz, 
9H, tBu-Si), -0.05 (d, J = 4.1 Hz, 6H, 2×Me-Si). 
 
13C NMR (63 MHz, CDCl3) δ 118.8 (C, C≡N), 69.1 (CH, C-8), 55.2 (CH), 52.7 (CH), 
42.0 (C, C-13), 40.2 (CH2), 34.1 (CH2), 33.0 (CH), 27.1 (CH2), 25.7 (3×CH3, 
tBu-Si), 
24.5 (CH2), 22.8 (CH2), 19.1 (CH3, C-21), 17.9 (C, Si), 17.40 (CH2), 13.7 (CH3, C-18),  
-5.0 (CH3, Me-Si), -5.3 (CH3, Me-Si). 
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1H NMR (250 MHz, CDCl3) δ 9.70 (dd, J = 3.4, 1.4 Hz, 1H, 
CHO), 3.96 (s, 1H, H-8), 2.41 (d, J = 14.0 Hz, 1H), 2.16 – 1.85 
(m, 3H), 1.79 – 1.51 (m, 4H), 1.39 – 1.09 (m, 7H), 0.95 (d,  
J = 6.4 Hz, 3H, Me-21), 0.92 (s, 3H, Me-18), 0.85 (s, 9H, tBu-Si), 
-0.04 (d, J = 3.6 Hz, 6H, 2×Me-Si). 
 
13C NMR (63 MHz, CDCl3) δ 203.5 (CH, CHO), 69.3 (CH, C-8), 56.5 (CH), 53.0 (CH), 
50.8 (CH2), 42.3 (C, C-13), 40.5 (CH2), 34.31 (CH2), 31.24 (CH), 27.54 (CH2), 25.78 
(3×CH3, 
tBu-Si), 23.0 (CH2), 20.0 (CH3, C-21), 18.0 (C, Si), 17.6 (CH2), 13.7 (CH3,  
C-18), -4.8 (CH3, Me-Si), -5.2 (CH3, Me-Si)  
 
  
FCUP | ICBAS | USC 
Supplementary Information 
91 
 
1H NMR (250 MHz, CDCl3) δ 5.84 – 5.62 (m, 1H, H-23), 4.95  
(d, J = 13.3 Hz, 2H, H-24), 3.97 (s, 1H, H-8), 2.15 (d, J = 12.5 
Hz, 1H), 1.99 – 1.44 (m, 7H), 1.40 – 1.19 (m, 5H), 1.12 – 0.95 
(m, 2H), 0.88 (d, J = 7.2 Hz, 15H, Me-21, Me-18, tBu-Si), -0.02 
(d, J = 2.8 Hz, 6H, 2×Me-Si). 
 
13C NMR (63 MHz, CDCl3) δ 137.5 (CH, C-23), 115.57 (CH2, C-24), 69.47 (CH, C-8), 
56.4 (CH), 53.0 (CH), 42.1 (C, C-13), 40.6 (CH2), 40.5 (CH2), 35.3 (CH), 34.5 (CH2), 
27.3 (CH2), 25.8 (3×CH3, 
tBu-Si), 23.1 (CH2), 18.6 (CH3, C-21), 18.0 (C, C-Si), 17.7 
(CH2), 13.8 (CH3, C-18), -4.8 (CH3, Me-Si), -5.2 (CH3, Me-Si).  
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1H NMR (250 MHz, CDCl3) δ 5.81 – 5.62 (m, 1H, H-23), 4.93  
(d, J = 12.6 Hz, 2H, H-24), 4.02 (s, 1H, H-8), 2.19 – 2.06 (m, 1H), 
2.00 – 1.89 (m, 1H), 1.86 – 1.65 (m, 4H), 1.52 – 1.22 (m, 8H), 
1.16 – 1.00 (m, 2H), 0.89 (s, 3H, Me-18), 0.86 (d, J = 8.0 Hz, 3H, 
Me-21). 
 
13C NMR (63 MHz, CDCl3) δ 137.2 (CH, C-23), 115.7 (CH2, C-24), 69.2 (CH, C8), 56.1 
(CH), 52.5 (CH), 41.8 (C, C13), 40.4 (CH2), 40.2 (CH2) 35.2 (CH), 33.52 (CH2), 27.0 
(CH2), 22.5 (CH2), 18.4 (CH3, Me-21), 17.4 (CH2), 13.5 (CH3, Me-18). 
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1H NMR (250 MHz, CDCl3) δ 5.80 – 5.56 (m, 1H, H-23), 4.95  
(d, J = 12.6 Hz, 2H, H-24), 2.40 (dd, J = 11.5, 7.5 Hz, 1H),  
2.27 – 1.98 (m, 4H), 1.97 – 1.62 (m, 5H), 1.57 – 1.24 (m, 5H), 
0.91 (d, J = 6.1 Hz, 3H, Me-21), 0.59 (s, 3H, Me-18). 
 
13C NMR (63 MHz, CDCl3) δ 211.9 (C, C-8), 136.7 (CH, C-23), 116.0 (CH2, C-24), 61.8 
(CH), 56.1 (CH), 49.8 (C, C-13), 40.9 (CH2), 40.3 (CH2), 38.8 (CH2), 35.4 (CH), 27.4 
(CH2), 24.0 (CH2), 19.0 (CH2), 18.6 (CH3, Me-21), 12.4 (CH3, Me-18). 
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1H NMR (250 MHz, CDCl3) δ 5.89 – 5.67 (m, 1H, H-23), 5.65  
(s, 1H, H-7), 4.99 (d, J = 13.6 Hz, 2H, H-24), 2.87 (dd, J = 11.0, 
2.5 Hz, 1H), 2.24 – 2.13 (m, 1H), 2.03 – 1.80 (m, 4H),  
1.69 – 1.44 (m, 6H), 1.36 – 1.23 (m, 3H), 0.94 (d, J = 6.5 Hz, 3H, 
Me-21), 0.57 (s, 3H, Me-18). 
 
13C NMR (63 MHz, CDCl3) δ 145.0 (C-8), 137.0 (CH, C-23), 115.9 (CH2, C24), 97.4 
(CH, C-7), 55.8 (CH), 55.3 (CH), 45.4 (C, C-13), 40.5 (CH), 39.7 (CH), 35.9 (CH), 31.0 
(CH2), 27.5 (CH2), 22.5 (CH2), 22.0 (CH2), 18.7 (CH3, Me-21), 11.8 (CH3, Me-18).  
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 1H NMR (400 MHz, cdcl3) δ 5.73 (s, 1H, H-23), 4.95 (d, J = 13.4 
Hz, 2H, H-24), 4.88 (s, 1H, H-7), 3.14 (d, J = 12.9 Hz, 1H), 2.15 
(d, J = 11.0 Hz, 1H), 2.04 – 1.41 (m, 13H), 1.23 (s, 12H, 
4×CH3COB), 0.90 (s, 3H, Me-21), 0.53 (s, 3H, Me-18). 
 
13C NMR (63 MHz, CDCl3) δ 166.2 (C, C-8), 137.3 (CH, C-23), 115.7 (CH2, C-24), 82.5 
(C, 2×COB), 57.9 (CH), 56.3 (CH), 46.2 (C, C-13), 40.5 (CH2), 40.3 (CH2), 36.0 (CH), 
33.2 (CH2), 27.4 (CH2), 24.9 (CH3, 2×COB), 24.8 (CH3, 2×COB), 24.3 (CH2), 22.3 
(CH2), 18.7 (CH3, Me-21), 12.1 (CH3, Me-18). 
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1H NMR (400 MHz, CDCl3) δ 6.38 (d, J = 11.2 Hz, 1H, H-6), 6.02 
(d, J = 11.3 Hz, 1H, H-7), 5.83 – 5.71 (m, 1H, H-23), 5.33 (s, 1H, 
H-19), 4.99 (d, J = 11.8 Hz, 3H, H-19, H-24), 4.43 (dd, J = 7.4, 
4.3 Hz, 1H, H-1), 4.26 – 4.20 (m, 1H, H-3), 2.82 (dd, J = 11.9, 
3.6 Hz, 1H), 2.59 (dd, J = 13.3, 2.9 Hz, 1H), 2.31 (dd, J = 13.4, 
6.5 Hz, 1H), 2.18 (d, J = 13.5 Hz, 1H), 2.03 – 1.85 (m, 6H), 1.67 
(d, J = 10.8 Hz, 5H), 1.53 – 1.44 (m, 4H), 1.34 – 1.25 (m, 4H), 
0.93 (d, J = 6.6 Hz, 3H, Me-21), 0.55 (s, 3H, Me-18). 
 
13C NMR (63 MHz, CDCl3) δ 147.6 (C, C-10), 143.2 (C, C-8), 137.3 (CH, C-23), 132.9 
(C, C-5), 125.0 (CH,C-6), 117,0 (CH, C-7), 115,8 (CH2, C-24) 111.8 (CH2, C-19), 70.8 
(CH, C-OH), 66.8 (CH, C-OH), 56.3 (CH), 56.0 (CH), 45.9 (C, C-13), 45.2 (CH2), 42.8 
(CH2), 40.5 (CH2), 40.3 (CH2), 36.1 (CH), 29.1 (CH2), 27.6 (CH2), 23.6 (CH2), 22.3 
(CH2), 18.7 (CH3, Me-21), 12.0 (CH3, Me-18).  
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1H NMR (400 MHz, cdcl3) δ 6.59 (ddd, J = 17.8, 7.9, 5.9 Hz, 1H, 
H-23), 6.37 (d, J = 11.2 Hz, 1H, H-6), 6.01 (d, J = 11.2 Hz, 1H, 
H-7), 5.42 (d, J = 17.9 Hz, 1H, H-24), 5.32 (s, 1H, H-19), 5.00  
(s, 1H, H-19), 4.43 (dd, J = 7.6, 4.3 Hz, 1H, H-1), 4.22  
(dt, J = 9.9, 3.3 Hz, 1H, H-3), 2.82 (d, J = 12.7 Hz, 1H), 2.60  
(d, J = 10.5 Hz, 1H), 2.31 (dd, J = 13.4, 6.7 Hz, 2H), 2.05 – 1.86 
(m, 7H), 1.68 – 1.45 (m, 10H), 1.27 (s, 12H, 4×CH3COB), 0.93 
(d, J = 6.5 Hz, 3H, Me-21), 0.54 (s, 3H, Me-18). 
 
13C NMR (63 MHz, CDCl3) δ 153.3 (CH, C-23), 147.6 (C, C-10), 143.1 (C, C-8), 132.8 
(C, C-5), 124.9 (CH, C-6), 117.0 (CH, C-7), 111.8 (CH2, C-19), 83.0 (C, COB), 70.8 
(CH), 66.8 (CH), 56.2 (CH), 56.1 (CH), 45.9 (C, C-13), 45.2 (CH2) 42.8 (CH2), 40.3 
(CH2), 35.9 (CH), 29.0 (CH2), 27.6 (CH2), 24.8 (CH3, 4×COB), 23.5 (CH2), 22.2 (CH2), 
19.1 (CH3, C-21), 12.0 (CH3, C-18). 
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7. Index of Structures 
 
 
